Wednesday, January 09, 2008 9:11:45 PM
<<I would imagine that an additional @ 1.5M shares will not affect many... especially if those shares come directly from the company.>>
You don't think fresh purchases of 1.5 mm shares - actually I get 1.66 mm shares for 13% of the outstanding - would put upward pressure on the stock price? Why not? Even if they are bought from Repros Treasury stock they help out the cash position, and it is likely that that cash question explains why the pps has been so miserable of late.
Their interests would seem to be aligned with other shareholders and management - get the best price at the right time - unless anyone knows something different.
Clearly if they lost heart and dumped all their stock they would cream the pps - just as buying takes us the other way. But they would be the biggest losers if they did this, so it won't happen lightly. And presumably there are some rules on this that go along with the standstill agreement. It's not ideal to be in the hands or judgment of a single player, but beggars can't be choosers. By the end of this year, if not well before, the information imperfections on Repros should be much reduced and then perhaps the market will attract some other buyers.
You don't think fresh purchases of 1.5 mm shares - actually I get 1.66 mm shares for 13% of the outstanding - would put upward pressure on the stock price? Why not? Even if they are bought from Repros Treasury stock they help out the cash position, and it is likely that that cash question explains why the pps has been so miserable of late.
Their interests would seem to be aligned with other shareholders and management - get the best price at the right time - unless anyone knows something different.
Clearly if they lost heart and dumped all their stock they would cream the pps - just as buying takes us the other way. But they would be the biggest losers if they did this, so it won't happen lightly. And presumably there are some rules on this that go along with the standstill agreement. It's not ideal to be in the hands or judgment of a single player, but beggars can't be choosers. By the end of this year, if not well before, the information imperfections on Repros should be much reduced and then perhaps the market will attract some other buyers.
Recent RPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:48:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 08:01:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 09:49:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 01:20:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:23:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 08:38:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 09:22:49 PM
- Form 13F-NT - Quarterly report filed by institutional managers, Notice • Edgar (US Regulatory) • 05/14/2026 06:29:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:14:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:12:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:10:50 PM
- Royalty Pharma to present at upcoming investor conferences • GlobeNewswire Inc. • 05/07/2026 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 01:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:31:54 AM
- Royalty Pharma reports first quarter 2026 results • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/30/2026 09:54:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/28/2026 09:00:16 PM
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation • GlobeNewswire Inc. • 04/21/2026 05:00:00 PM
- Royalty Pharma Declares Second Quarter 2026 Dividend • GlobeNewswire Inc. • 04/17/2026 12:30:00 PM
- Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 • GlobeNewswire Inc. • 04/15/2026 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 01:53:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2026 08:11:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 08:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:58:57 PM
